Safety and Pharmacology of Stanate

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Hyperbilirubinemia
Interventions
DRUG

Stanate

Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion

Trial Locations (1)

Unknown

National hospital of pediatrics, Hanoi

All Listed Sponsors
collaborator

National Children's Hospital, Vietnam

OTHER

lead

InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

INDUSTRY

NCT00115544 - Safety and Pharmacology of Stanate | Biotech Hunter | Biotech Hunter